Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has announced an Early Access Program for a new spatial protein proximity detection assay, built on RNAscope™ technology. The next-generation assay enables high-resolution visualization of protein interactions within intact tissues, providing functional insights into disease processes.

The technology addresses limitations of conventional methods by offering clear visual signals at subcellular resolution, compatible with the RNAscope™ Multiomic LS workflow on BOND RX. This advancement is particularly valuable for research in immune checkpoint dynamics, bispecific antibodies, and synaptic junction protein interactions.

The Early Access Program will be available to select institutions and researchers, with proof-of-concept data and case studies to be presented at the 2025 American Association for Cancer Research (AACR) annual meeting.

Positive

• Introduction of innovative spatial protein proximity detection technology expanding product portfolio
• Early Access Program launch demonstrates market readiness and commercial potential
• Technology addresses existing limitations in conventional research methods

Negative

• Early stage of commercialization with revenue impact in near term
• Success dependent on adoption by research institutions and validation of technology

News Market Reaction

+1.24%

1 alert

+1.24% News Effect

On the day this news was published, TECH gained 1.24%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues

MINNEAPOLIS, April 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity. Built upon Advanced Cell Diagnostics RNAscope™ technology, this next-generation assay is designed to reveal functional interactions between proteins within intact tissues, delivering a spatial solution to explore how molecular signaling shapes disease processes — offering a truly integrated spatial multiomic view.

"This new protein proximity assay opens the door to seeing functional interactions between proteins and not merely their presence in a tissue," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "It's a powerful step forward in understanding the dynamic interplay within tissues that drives biology and disease."

Conventional methods for studying molecular interactions in tissues that separately measure proteins and RNA risk losing spatial fidelity, while bulk proximity assays provide no localization data. Bio-Techne's proximity detection technology addresses these gaps with a clear visual signal at subcellular resolution, built to be compatible with the RNAscope™ Multiomic LS workflow on BOND RX. This capability is particularly valuable for research areas where context matters — such as assessing immune checkpoint dynamics, investigating bispecific antibodies and studying protein interactions at synaptic junctions.

The Early Access Program is available to select institutions and researchers interested in incorporating spatial protein proximity capabilities into their workflows. Proof-of-concept data and case studies will be shared at the 2025 American Association for Cancer Research (AACR) annual meeting, presented by Bio-Techne's scientific team.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com 
612-656-4416

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-early-access-program-for-next-generation-spatial-protein-proximity-detection-302436484.html

SOURCE Bio-Techne Corporation

FAQ

What is Bio-Techne's new spatial protein proximity detection technology?

It's a next-generation assay that enables high-resolution visualization of protein interactions within intact tissues, built on RNAscope™ technology, providing functional insights into disease processes.

How does TECH's new protein proximity assay differ from conventional methods?

Unlike conventional methods that separately measure proteins and RNA or bulk proximity assays without localization data, this technology provides clear visual signals at subcellular resolution while maintaining spatial context.

What research applications will benefit from Bio-Techne's (TECH) new protein proximity assay?

The technology is particularly valuable for research in immune checkpoint dynamics, bispecific antibodies investigation, and studying protein interactions at synaptic junctions.

When will Bio-Techne present data for their new spatial protein detection technology?

Bio-Techne will present proof-of-concept data and case studies at the 2025 American Association for Cancer Research (AACR) annual meeting.